Neogen's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Neogen in the fourth quarter 2026?
Neogen Corporation recorded a cumulative net loss of $-8 million during 12 months ending in the fourth quarter 2026, resulting in a negative return on equity (ROE) of -0.38%.

Within the In Vitro & In Vivo Diagnostic Substances industry only one company had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2026 from 2265 to 3007.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(May 31 2026) IV. Quarter	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter	(May 31 2025) IV. Quarter
Y / Y Equity Change	1.05 %	-20.97 %	-34.12 %	-32.42 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-8	-609	-603	-1,043	-1,092
Return On Equity (TTM)	-0.38 %	-29.12 %	-27.02 %	-41.75 %	-39.67 %
NEOG's Total Ranking	# 3007	# 2265	# 61	# 2754	# 2724
Equity (TTM) in Millions	2,093	2,102	2,071	2,119	2,071
Seq. Equity Change	-0.45 %	1.5 %	-2.24 %	2.29 %	-22.14 %
Seq. Net Income Change	-	-	-	-	-

Back to NEOG Management Effectiveness >> NEOG's 5 Years Annual ROE >> Compare NEOG ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 2
Sector	# 196
Overall	# 3007

Return On Equity Statistics
High	Average	Low
12.07 %	3.49 %	-41.75 %
(Aug 31 2018)		(Aug 31 2025)

NEOG Annual Return On Equity	(May 31 2026) 2026	(May 31 2025) 2025	(May 31 2024) 2024	(May 31 2023) 2023	(May 31 2022) 2022
Total Equity in Millions	2,093	2,071	3,144	3,134	887
Y / Y Equity Change	1.05 %	-34.12 %	0.32 %	253.2 %	5.59 %
Net Income in Millions	-8	-1,092	-9	-23	48
Y / Y Net Income Change	-	-	-	-	-20.65 %
Return On Equity	-0.38 %	-52.72 %	-0.3 %	-0.73 %	5.44 %

Back to NEOG Management Effectiveness >> NEOG's 5 Years Annual ROE >> Compare NEOG ROE to its Competitors

More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NEOG's' Return on Equity at Yahoo Finance
NEOG's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NEOG's Competitors
Subscribers only: Roe for Neogen's Suppliers
Subscribers only: Return On Equity for NEOG's Customers

Companies with similar Return On Equity at May 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T09:58:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.